MOLN Molecular Partners

Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference

Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the fourth quarter and full year of 2022, followed by an investor call the following day. Chief Executive Officer Patrick Amstutz will also deliver a company presentation at the 43rd Annual Cowen Health Care Conference in Boston, MA. Please see all details below:

Conference Presentation Details:

Cowen Health Care Conference

March 8, 2023, at 9:10am ET (3:10pm CET)

Boston, MA

Full Year 2022 Release Date and Time:

March 9, 2023, 4:00 pm ET (10:00 pm CET)

Call Details:

March 10, 2023, 8:00 am ET (2:00 pm CET)

The full year 2022 results presentation will also be webcast live and will be made available on the Company’s website under the . The replay will be available for 90 days following the presentation.

In order to register for the full year 2022 conference call on March 10, 2pm CET / 8am ET, please dial the following numbers approximately 10 minutes before the start of the presentation:

Switzerland0800-246787
  
  
USA1-866-652-5200
  
  
Full list of dial-in numbers:Linked
  
  
Conference IDPlease ask to be joined into the Molecular Partners call.
  



About Molecular Partners AG 

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. ; Find us on Twitter -

For further details, please contact:

Seth Lewis



Tel:



Antonio Ligi, Head of Communications

Zurich-Schlieren, Switzerland

 

Tel: 1



EN
02/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Co...

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present the Company’s latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco, CA, USA. Chief Executive Officer Patrick Amstutz will pres...

 PRESS RELEASE

Molecular Partners Forms Scientific Advisory Board to Accelerate Devel...

Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drug...

 PRESS RELEASE

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial...

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant...

Molecular Partners AG: 1 director

A director at Molecular Partners AG sold 35,000 shares at 0.000CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy M...

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host confer...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch